← Back to Search

Kinase Inhibitor

Lapatinib and RAD-001 for Breast Cancer

Phase 2
Waitlist Available
Led By Qamar Khan, MD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

By doing this study, researchers hope to learn the effectiveness of the combination of Lapatinib and RAD-001 for treating patients who have progressed on previous therapies.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the effectiveness of the combination of RAD-001 and lapatinib
Secondary outcome measures
Overall benefit of combination

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lapatinib and RAD-001Experimental Treatment1 Intervention
RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day. Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state.

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
460 Previous Clinical Trials
169,092 Total Patients Enrolled
23 Trials studying Breast Cancer
4,510 Patients Enrolled for Breast Cancer
NovartisIndustry Sponsor
1,610 Previous Clinical Trials
2,719,247 Total Patients Enrolled
57 Trials studying Breast Cancer
21,188 Patients Enrolled for Breast Cancer
GlaxoSmithKlineIndustry Sponsor
4,750 Previous Clinical Trials
8,067,429 Total Patients Enrolled
32 Trials studying Breast Cancer
2,326,304 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
2011. "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01283789.
All > Metastatic Breast Cancer > Afinitor
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top